KR920006003A - 비강용 약학적 조성물 - Google Patents

비강용 약학적 조성물 Download PDF

Info

Publication number
KR920006003A
KR920006003A KR1019910016588A KR910016588A KR920006003A KR 920006003 A KR920006003 A KR 920006003A KR 1019910016588 A KR1019910016588 A KR 1019910016588A KR 910016588 A KR910016588 A KR 910016588A KR 920006003 A KR920006003 A KR 920006003A
Authority
KR
South Korea
Prior art keywords
cellulose
hpth
composition
carrier
coated
Prior art date
Application number
KR1019910016588A
Other languages
English (en)
Inventor
꺄르디노 프랑스와
외흐슐라인 크리스틴
루멜트 안드레아스
Original Assignee
예안 크라메르·한스 루돌프 하우스
산도즈 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 예안 크라메르·한스 루돌프 하우스, 산도즈 리미티드 filed Critical 예안 크라메르·한스 루돌프 하우스
Publication of KR920006003A publication Critical patent/KR920006003A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Abstract

내용 없음

Description

비강용 약학적 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (17)

  1. [1-35]hPTH, [1-36]hPTH 및 [1-38]hPTH 내지 [1-4]hPTH 에서 선택된 hPTH 단편 또는 그것의 유사화합물 또는 유도체를 포함하는 비강용 약학적 조성물.
  2. [1-34]hPTH 내지 [1-4]hPTH 에서 선택된 hPTH 단편 또는 그것의 유사화합물 또는 유도체와 흡수증진제 또는 계면활성제 부재하에 담체를 포함하는 비강용 약학적 조성물.
  3. 제2항에 있어서, 상기 담체가 폴리아크릴레이트, 전분 또는 그 유도체, 알긴산 또는 그염, 히일루론산 또는 그염, 펙틴산 또는 그염, 젤라틴 또는 그 유도체, 고무류, 다가젖산 또는 그 공중합체, 폴리비닐아세테이트, 셀룰로오즈 또는 그 유도체, 피복셀룰로우즈 또는 가교결합된 텍스트란인 조성물.
  4. 제2항에 있어서, 상기 담체가 셀루로오즈, α-셀루로오즈, 미세결정형 셀룰로오즈, 피복셀룰로오즈, 피복 α-셀룰로오즈 또는 피복미세결정형 셀룰로오즈인 조성물.
  5. 제2항에 있어서, 상기 조성물의 0.1 내지 99.9 중량(또는 부피) %의 담체를 포함하는 조성물.
  6. 제2항에 있어서, 상기 담체가 셀룰로오즈 1 내지 15중량%의 피복제로 피복된 셀룰로오즈인 조성물.
  7. 제2항에 있어서, 상기 담체가 포화 또는 불포화 C15-C22지방산의 글리세리드로 피복된 셀룰로오즈인 조성물.
  8. 제2항에 있어서, 투여제형당 1 내지 30mg의 담체를 포함하는 조성물.
  9. [1-34]hPTH 내지 [1-4]hPTH 중에서 선택된 hPTH 단편과 흡수증진제 또는 계면활성제를 포함하고 액상 또는 고형담체를 임의로 포함하며, 단편이 [1-34]hPTH 일 경우에는 상기 흡수증진제 또는 계면활성제가 글리시리지네이트인 비강용 약학적 조성물.
  10. 제9항에 있어서, 상기 흡수증진제 또는 계면활성제가 0.5 내지 10중량%정도 존재하는 조성물.
  11. 제2항 또는 제9항에 있어서, 비강용분무제, 점적제, 겔, 분말 또는 비강용 삽입제 형태인 조성물.
  12. 포화 또는 불포화 C15-22지방산의 글리세리드로 피복된 셀룰로오즈.
  13. 제12항에 있어서, 셀룰로오즈, α-셀룰로오즈 또는 미세결정형 셀룰로오즈를 포함하는 셀룰로오즈.
  14. 생리학적 활성 펩티드 및 피복셀룰로오즈를 포함하는 분말형태의 비강용 약학적 조성물.
  15. 제14항에 있어서, 상기 펩티드가 hPTH, 칼시토닌, 또는 소마토스타틴 또는 그들의 유사 화합물 또는 유도체인 조성물.
  16. 유리형태 또는 염 또는 착물형태의 하기 일반식(Ⅰ) 화합물 :
    상기식에서, X1은 Ser 또는 Ala이고 X2는 Leu 또는 Ala이며 X3은 OH 또는 NH2이다.
  17. 약학적 담체 또는 희석제와 함께 제16항에서 정의한 유리형태 또는 약학적 허용염 형태 또는 착물형태의 일반식(Ⅰ) 화합물을 포함하는 약학적 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019910016588A 1990-09-20 1991-09-19 비강용 약학적 조성물 KR920006003A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9020544.4 1990-09-20
GB909020544A GB9020544D0 (en) 1990-09-20 1990-09-20 Improvements in or relating to organic compounds

Publications (1)

Publication Number Publication Date
KR920006003A true KR920006003A (ko) 1992-04-27

Family

ID=10682494

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910016588A KR920006003A (ko) 1990-09-20 1991-09-19 비강용 약학적 조성물

Country Status (21)

Country Link
US (1) US5578567A (ko)
EP (2) EP0490806A3 (ko)
JP (1) JPH04247034A (ko)
KR (1) KR920006003A (ko)
AT (1) ATA189691A (ko)
AU (1) AU8464791A (ko)
CA (1) CA2051721A1 (ko)
CH (1) CH683749A5 (ko)
CS (1) CS285491A3 (ko)
DE (1) DE4131232A1 (ko)
FI (1) FI914398A (ko)
FR (2) FR2666987A1 (ko)
GB (2) GB9020544D0 (ko)
IE (1) IE913296A1 (ko)
IL (1) IL99521A0 (ko)
IT (1) IT1255258B (ko)
LU (1) LU88006A1 (ko)
MX (1) MX9101175A (ko)
NO (1) NO913668D0 (ko)
PT (1) PT99007A (ko)
ZA (1) ZA917528B (ko)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3090353B2 (ja) * 1991-09-17 2000-09-18 旭化成工業株式会社 パラチロイドホルモン類含有経鼻投与用乳剤
ES2129048T3 (es) * 1991-12-09 1999-06-01 Asahi Chemical Ind Composicion estabilizada de hormona paratiroide.
DE4203040A1 (de) * 1992-02-04 1993-08-05 Boehringer Mannheim Gmbh Neue parathormonfragmente, deren herstellung und diese enthaltende arzneimittel
US5482706A (en) * 1992-04-17 1996-01-09 Takeda Chemical Industries, Ltd. Transmucosal therapeutic composition
US5977070A (en) * 1992-07-14 1999-11-02 Piazza; Christin Teresa Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
AU672790B2 (en) * 1992-07-15 1996-10-17 Novartis Ag Variants of parathyroid hormone and its fragments
GB2269992A (en) * 1992-08-14 1994-03-02 Rh Ne Poulenc Rorer Limited Powder inhalation formulations
ATE220327T1 (de) 1992-09-29 2002-07-15 Inhale Therapeutic Syst Pulmonale abgabe von aktiven fragmenten des parathormons
US5482931A (en) * 1993-06-29 1996-01-09 Ferring Ab Stabilized pharmaceutical peptide compositions
US5496801A (en) * 1993-12-23 1996-03-05 Allelix Biopharmaceuticals Inc. Parathyroid hormone formulation
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US6117455A (en) * 1994-09-30 2000-09-12 Takeda Chemical Industries, Ltd. Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent
DK0806945T3 (da) * 1994-12-22 2003-08-04 Astrazeneca Ab Terapeutisk præparat til inhalering, indeholdende parathyroideahormon, PTH
JP3098401B2 (ja) * 1995-07-12 2000-10-16 株式会社エルティーティー研究所 経鼻投与用製剤
JP3263598B2 (ja) * 1995-11-01 2002-03-04 有限会社ドット 経鼻吸収用生理活性ペプチド組成物
CN1095681C (zh) * 1996-06-20 2002-12-11 久光制药株式会社 一种用于离子电渗疗法的装置结构
TW505654B (en) * 1996-07-30 2002-10-11 Hoffmann La Roche Synthesis of analogs of PTH and PTHrP
SE9702401D0 (sv) 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
EP1721617A3 (en) * 1997-07-22 2008-05-28 Chugai Seiyaku Kabushiki Kaisha Dental therapeutics containing parathyroid hormone
US7923250B2 (en) 1997-07-30 2011-04-12 Warsaw Orthopedic, Inc. Methods of expressing LIM mineralization protein in non-osseous cells
CA2297489A1 (en) 1997-07-30 1999-02-11 Emory University Novel bone mineralization proteins, dna, vectors, expression systems
US6770623B1 (en) 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
MY120063A (en) * 1997-12-09 2005-08-30 Lilly Co Eli Stabilized teriparatide solutions
DE19756314C2 (de) * 1997-12-12 2000-06-29 Roland Bodmeier Zubereitung mit verlängerter Verweildauer am Applikationsort
JPH11246439A (ja) * 1998-03-02 1999-09-14 Hisamitsu Pharmaceut Co Inc 経粘膜用吸収促進剤
CN1065141C (zh) * 1998-05-20 2001-05-02 北京金源东和化学有限责任公司 通过鼻粘膜给药的药物制剂
WO1999059543A1 (en) * 1998-05-20 1999-11-25 Highchem Company., Ltd. A pharmaceutical formulation for nasal administration
US6150420A (en) * 1998-06-01 2000-11-21 Theramax, Inc. Method for enhanced brain delivery of bupropion
AU762145C (en) * 1998-08-26 2005-03-17 Teijin Limited Powdery pernasal compositions
JP2000239187A (ja) * 1999-02-22 2000-09-05 Dotto:Kk 経鼻吸収用組成物
JP2000247911A (ja) 1999-02-26 2000-09-12 Hisamitsu Pharmaceut Co Inc 大腸用吸収促進剤
AU4979700A (en) * 1999-05-03 2000-11-17 Battelle Memorial Institute Compositions for aerosolization and inhalation
US6197328B1 (en) * 1999-08-20 2001-03-06 Dott Research Laboratory Nasally administrable compositions
ES2166278B2 (es) * 1999-09-14 2003-06-16 Univ Madrid Complutense Procedimiento de preparacion de polvos nasales por atomizacion utilizando excipientes insolubles y absorbentes como promotores de absorcion nasal.
CN1431919A (zh) * 2000-04-03 2003-07-23 巴特勒记忆研究所 装置和制剂
CA2414966A1 (en) * 2000-06-30 2002-01-10 Suntory Limited A pharmaceutical component based on human parathyroid hormone and a pharmaceutical composition for intranasal administration containing the component
EP1343521A2 (en) * 2000-12-01 2003-09-17 Battelle Memorial Institute Method for the stabilizing biomolecules (e.g. insulin) in liquid formulations
DE10120200B4 (de) * 2001-04-24 2005-12-22 Infood Gmbh Schnupfpulver als Schnupftabakersatz
EP1509209A1 (en) * 2002-05-23 2005-03-02 UMD, Inc. Compositions and method for transmucosal drug delivery and cryoprotection
US7273889B2 (en) * 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
US7164005B2 (en) * 2002-10-17 2007-01-16 Alkermes, Inc. Microencapsulation and sustained release of biologically active polypeptides
GB0304636D0 (en) * 2003-02-28 2003-04-02 Britannia Pharmaceuticals Ltd Pharmaceutical composition for nasal delivery
US7683029B2 (en) * 2003-05-07 2010-03-23 Philip Morris Usa Inc. Liquid aerosol formulations containing insulin and aerosol generating devices and methods for generating aerosolized insulin
US20060189533A1 (en) * 2004-05-10 2006-08-24 Nastech Pharmaceutical Company Inc. Stable pharmaceutical dosage forms of teriparatide
US20060052306A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. GRAS composition for enhanced mucosal delivery of parathyroid hormone
US20060127320A1 (en) * 2004-05-10 2006-06-15 Nastech Pharmaceutical Company Inc. Method of delivering parathyroid hormone to a human
US20060052305A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. Method of treating osteoporosis using intranasal parathyroid hormone
AU2005247369A1 (en) * 2004-05-10 2005-12-08 Mdrna, Inc. Compositions and methods for enhanced mucosal delivery of parathyroid hormone
US7906137B2 (en) * 2004-05-21 2011-03-15 Mediplex Corporation, Korea Delivery agents for enhancing mucosal absorption of therapeutic agents
EP1779864A4 (en) * 2004-07-14 2010-10-20 Chugai Pharmaceutical Co Ltd PTH-CONSIDERED PREPARATION FOR TRANSMUCOSAL ADMINISTRATION
US20060069021A1 (en) * 2004-08-13 2006-03-30 Nastech Pharmaceutical Company Inc. Compositions and methods for intranasal administration of inactive analogs of PTH or inactivated preparations of PTH or PTH analogs
US7115561B2 (en) * 2004-09-22 2006-10-03 Patterson James A Medicament composition and method of administration
US20090136505A1 (en) 2005-02-23 2009-05-28 Johanna Bentz Intranasal Administration of Active Agents to the Central Nervous System
CA2598666A1 (en) * 2005-02-23 2006-08-31 Alza Corporation Intranasal administration of active agents to the central nervous system
US20090042790A1 (en) * 2005-06-13 2009-02-12 Nastech Pharmaceutical Company Inc. Transmucosal delivery of peptide derivatives
EP1931374A2 (en) * 2005-10-06 2008-06-18 Nastech Pharmaceutical Company Inc. Pth formulations and methods of use
WO2007044375A2 (en) * 2005-10-06 2007-04-19 Nastech Pharmaceutical Company Inc. Pth formulations and methods of use
US20070173447A1 (en) * 2005-10-25 2007-07-26 Nastech Pharmaceutical Company Inc. Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent
EP1945245A2 (en) 2005-11-10 2008-07-23 The Board of Control of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US20080051332A1 (en) * 2005-11-18 2008-02-28 Nastech Pharmaceutical Company Inc. Method of modulating hematopoietic stem cells and treating hematologic diseases using intranasal parathyroid hormone
US20080119408A1 (en) * 2006-07-07 2008-05-22 Nastech Pharmaceutical Company Inc. Pth formulations for intranasal delivery
WO2008065144A2 (en) * 2006-11-29 2008-06-05 Novartis Ag Galenic formulations of organic compounds
GB0715285D0 (en) * 2007-08-06 2007-09-12 Britannia Pharmaceuticals Ltd Improvements in or relating to powdered medicaments for nasal delivery
EP2106788A1 (en) * 2008-04-04 2009-10-07 Ipsen Pharma Liquid and freeze dried formulations
AU2009356227A1 (en) 2009-12-07 2012-06-21 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US8802622B2 (en) * 2010-03-19 2014-08-12 Daiichi Sankyo Company, Limited Composition for nasal administration and method for preparing same
US10723716B2 (en) 2016-12-21 2020-07-28 New York University Alpha-helix mimetics as modulators of Abeta self-assembly
US11124479B2 (en) 2017-07-14 2021-09-21 New York University Oligopyrroles as antagonists of islet amyloid polypeptide oligomerization
US10500197B2 (en) 2017-07-18 2019-12-10 New York University Use of oligopyridylamides to inhibit mutant p53 amyloid formation and restore its tumor suppressor function
WO2021229835A1 (ja) * 2020-05-11 2021-11-18 旭化成ファーマ株式会社 テリパラチド又はその塩を含有する安定な液状医薬製剤
AU2022209699A1 (en) * 2021-01-21 2023-07-13 Nbo Pharma Llc Intranasal formulations and delivery of somatostatin mimetics and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3243358A1 (de) * 1982-11-24 1984-05-24 Rolf Dieter Prof.Dr. 3004 Isernhagen Hesch Synthetisches humanes (1-38) parathormon-fragment, verfahren zu seiner herstellung und die verwendung zur behandlung der osteoporose
GB8514090D0 (en) * 1985-06-04 1985-07-10 Sandoz Ltd Organic compounds
FR2550204B1 (fr) * 1983-08-05 1987-11-13 Toyo Jozo Kk Derives peptidiques de (nle8,nle1b, tyr34)-h-pth
GB2193891B (en) * 1986-08-18 1990-07-25 Sandoz Ltd Nasal pharmaceutical composition containing a somatostatin anologue.
JPS6360940A (ja) * 1986-09-01 1988-03-17 Toyo Jozo Co Ltd 白内障の予防または治療剤
JPS63243033A (ja) * 1987-03-31 1988-10-07 Toyo Jozo Co Ltd 経鼻投与組成物
US5059587A (en) * 1987-08-03 1991-10-22 Toyo Jozo Company, Ltd. Physiologically active peptide composition for nasal administration
CA1336401C (en) * 1987-10-15 1995-07-25 Brian H. Vickery Intranasal administration of polypeptides in powdered form
ES2061688T3 (es) * 1987-11-13 1994-12-16 Smithkline Beecham Farma Composiciones farmaceuticas que comprenden una calcitonina y un glicirricinato como mejorador de la absorcion.
JPH0242027A (ja) * 1988-08-02 1990-02-13 Minofuaagen Seiyaku Honpo:Goushi 経粘膜吸収促進剤及びこれを用いた経鼻投与剤
JPH02104531A (ja) * 1988-10-14 1990-04-17 Toyo Jozo Co Ltd 経鼻投与用生理活性ペプチド組成物
US5190748A (en) * 1988-11-22 1993-03-02 Hoffmann-La Roche Inc. Absorption enhancement of antibiotics
US5011678A (en) * 1989-02-01 1991-04-30 California Biotechnology Inc. Composition and method for administration of pharmaceutically active substances
DK0465508T3 (da) * 1989-03-08 2000-08-07 Univ Virginia Diætsupplement til insulinresistente diabetikere
IT8920486A0 (it) * 1989-05-12 1989-05-12 Isf Spa Composizioni farmaceutiche.
DE4039656A1 (de) * 1990-12-12 1992-06-17 Bissendorf Peptide Gmbh Arzneimittel, enthaltend das humane parathormon-fragment (1-37) in der form des amids oder ethylamids als aktiven wirkstoff
US5317010A (en) * 1991-10-10 1994-05-31 Peter K. T. Pang Parathyroid hormone analogues substituted at AA 25, 26, 27, and use in osteoporosis treatment

Also Published As

Publication number Publication date
CS285491A3 (en) 1992-04-15
EP0672682A1 (en) 1995-09-20
FR2681326B1 (fr) 1995-06-16
NO913668D0 (no) 1991-09-18
JPH04247034A (ja) 1992-09-03
EP0490806A2 (en) 1992-06-17
CH683749A5 (de) 1994-05-13
FR2681326A1 (fr) 1993-03-19
GB2248550B (en) 1995-04-05
MX9101175A (es) 1992-05-04
FI914398A0 (fi) 1991-09-18
IE913296A1 (en) 1992-02-25
IL99521A0 (en) 1992-08-18
AU8464791A (en) 1992-03-26
CA2051721A1 (en) 1992-03-21
DE4131232A1 (de) 1992-03-26
FR2666987A1 (fr) 1992-03-27
PT99007A (pt) 1992-08-31
GB9020544D0 (en) 1990-10-31
ITRM910696A0 (it) 1991-09-18
IT1255258B (it) 1995-10-20
ITRM910696A1 (it) 1993-03-18
GB9120024D0 (en) 1991-11-06
EP0490806A3 (en) 1992-09-23
FI914398A (fi) 1992-03-21
ATA189691A (de) 1997-10-15
LU88006A1 (fr) 1993-04-15
GB2248550A (en) 1992-04-15
US5578567A (en) 1996-11-26
ZA917528B (en) 1993-03-22

Similar Documents

Publication Publication Date Title
KR920006003A (ko) 비강용 약학적 조성물
US4476116A (en) Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
EP1997497A3 (en) Compositions and methods for treating a posterior segment of an eye
EP0244178A3 (en) Intraocular dosage compositions and method of use
RU98104253A (ru) Новые опиоидные пептиды
NO2011006I1 (no) Pitavastin, valgfritt i form av av farmasøytisk akseptabelt salt eller ester
KR890700601A (ko) 펩티딜아미노디올
KR900700091A (ko) 누액 분비 자극제(lss)
KR910016739A (ko) 글리콜 산 유도체
NO871663D0 (no) Adhesiver avledet fra bioadhesive polyfenoliske proteiner.
KR900016253A (ko) 아미드화 타우린 또는 글리신의 산부가염, 그의 제조방법과 용도
KR920008066A (ko) 아미노산 유도체
IL83086A (en) Stable,injectable solutions of vincristine salts
AU558679B2 (en) Animal feed composition comprising alyl peptides
RU2003102629A (ru) Фармацевтический компонент на основе паратиреоидного гормона человека и содержащая его фармацевтическая композиция для интраназального применения
KR890016063A (ko) 아미노산 유도체
KR880002507A (ko) 페닐퀴놀린 카복실산의 동결건조 약제 조성물
RU94046058A (ru) Агент для лечения и профилактики катаракты, способ его получения, применение (+) - (2s, 3s)-3 (s)-3-метил-1-(3-метилбутилкарбомоил)бутилкарбамоил]-2-оксикарбоновой кислоты ее соли и ее этилового эфира для получения агента, способ лечения и профилактики катаракты, способ получения водного раствора
KR890000515A (ko) 식욕억제용 콜레시스토키닌 동족체
NZ505080A (en) Pharmaceutical formulations containing a compound having an amidine group stabilized by an acid
GB1499420A (en) Ergot peptide alkaloids
JP2001518510A (ja) デキサメタゾンゲル
KR900017610A (ko) 고나돌리베린 유도체를 함유하는 종양억제용 약제조성물의 제조방법
KR920004413A (ko) 아미노산 유도체
KR970070006A (ko) 2-아미노-6-플루오로-9-(2-하이드록시에톡시메틸)퓨린 에스테르 유도체

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid